Australia markets open in 9 hours 22 minutes

  • ALL ORDS

    6,971.60
    +28.60 (+0.41%)
     

  • AUD/USD

    0.7666
    -0.0016 (-0.21%)
     

  • ASX 200

    6,739.60
    +28.80 (+0.43%)
     

  • OIL

    65.93
    -0.16 (-0.24%)
     

  • GOLD

    1,692.00
    -6.50 (-0.38%)
     

  • BTC-AUD

    66,491.31
    +109.66 (+0.17%)
     

  • CMC Crypto 200

    1,029.83
    +86.66 (+9.19%)
     
Women's wealth:

YOU'RE INVITED: Breakfast and investing tips

Join Yahoo Finance and Thrive Global to harness your habits and secure your future.

Mesut Ozil excited about ‘dream come true’ Fenerbahce transfer from Arsenal

Karl Matchett
·2-min read
<p>Mesut Ozil</p> (Mesut Ozil / Twitter)

Mesut Ozil

(Mesut Ozil / Twitter)

Mesut Ozil is closing in on his move to Turkish Super Lig side Fenerbahce, having arrived in Istanbul to finalise talks.

The Arsenal attacking midfielder has been left out of both Premier League and Europa League squads this season and manager Mikel Arteta has made it clear there is no place for the former Germany international in his plans for the future.

That remains the case despite the Gunners reverting to a 4-2-3-1 system of late, with Emile Smith Rowe operating in the No. 10 role which Ozil would otherwise be a candidate to fill.

The former Real Madrid man has said his goodbyes to his team-mates at the Emirates Stadium, report Sky Sports, and spoke upon his arrival to Turkey as he prepares for his Fenerbahce medical.

READ MORE: Premier League fixtures and table - all matches by date and kick-off time

“I am very excited because I was always a fan of Fenerbahce. My dream comes true,” he said.

“I am very excited to wear the Fenerbahce jersey. I hope we will be very successful with my team-mates.”

Ozil further explained he hopes to repay the fans’ support with his performances on the pitch, though as it has been 10 months since he last participated in a competitive game he could potentially have to wait for a debut.

Talking to Turkish outlet NTV, Ozil acknowledged he is “missing a few matches” but says he is “physically fit” and “excited” about joining the club he is a fan of.

His current club Arsenal are in action on Monday night against Newcastle in the Premier League, hoping to move into the top half of the table with a victory.

The Gunners won the FA Cup at the end of last season and are on a four-match unbeaten streak in the league, but have largely unimpressed this season with a lack of creativity leading to calls from some quarters to reinstate Ozil to the team.

Arsenal knocked Newcastle out of the FA Cup last weekend, with Smith Rowe netting a decisive goal.

Read More

How to watch Arsenal vs Newcastle online and on TV tonight

Arteta concerned Arsenal players are suffering from burnout

City the only winners as Liverpool and United pay price for timidity

Latest stories

  • Olo Announces Launch of Initial Public Offering

    Olo Announces Launch of Initial Public Offering.

  • Deutsche Post announces share buyback up to $1.2 billion

    German logistics group Deutsche Post AG said on Monday it will buy back shares up to a total of 1 billion euros ($1.19 billion) for a one-year period starting in March to take advantage of its positive business trend. The purchased shares will either be cancelled or used to service long term management incentive programmes, it said in an ad hoc announcement. Deutsche Post said it will propose a dividend of 1.35 euros per share for 2020, up from 1.15 euros in 2019.

  • Frontdoor to Participate at the Truist Securities Technology, Internet & Services Conference

    Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home service plans, today announced it is attending the Truist Securities Technology, Internet & Services Conference, and that management will participate in a fireside chat to be held virtually on March 9, 2021.

  • Explainer: Why protests are shaking one of Africa's most stable democracies

    Clashes between police and thousands of demonstrators protesting at the detention of Senegal's most prominent opposition leader have killed at least five people since last week. Ousmane Sonko was indicted and released on bail under judicial supervision on Monday but an opposition coalition has called for three days of protests from Monday. The unrest is the worst in a decade in Senegal, widely seen as one of West Africa's most stable democracies.

  • Global Wearable Materials Market to Reach $5 Billion by 2027

    Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 9. - Influencer Pool: 962. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.New York, March 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Wearable Materials Industry" - https://www.reportlinker.com/p06033294/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: - Global Wearable Materials Market to Reach $5 Billion by 2027 - Amid the COVID-19 crisis, the global market for Wearable Materials estimated at US$1.9 Billion in the year 2020, is projected to reach a revised size of US$5 Billion by 2027, growing at a CAGR of 14.5% over the analysis period 2020-2027. Silicones, one of the segments analyzed in the report, is projected to record a 15.5% CAGR and reach US$2.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Fluoroelastomers segment is readjusted to a revised 12.8% CAGR for the next 7-year period. - The U.S. Market is Estimated at $573.6 Million, While China is Forecast to Grow at 13.9% CAGR - The Wearable Materials market in the U.S. is estimated at US$573.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$866.3 Million by the year 2027 trailing a CAGR of 13.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.8% and 12.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR. - Polyurethanes Segment to Record 14.6% CAGR - In the global Polyurethanes segment, USA, Canada, Japan, China and Europe will drive the 14.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$326.4 Million in the year 2020 will reach a projected size of US$838.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$594.3 Million by the year 2027. Select Competitors (Total 45 Featured) - 3MArkemaBASFCovestroDaikin ChemicalsDowdupontDSMEastman CorporationElkemEmerald Performance Materials Read the full report: https://www.reportlinker.com/p06033294/?utm_source=GNW I. METHODOLOGYII. EXECUTIVE SUMMARY1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Wearable Materials Competitor Market Share Scenario Worldwide (in %): 2020E Global Competitor Market Shares by Segment 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Wearable Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 2: World 7-Year Perspective for Wearable Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 Table 3: World Current & Future Analysis for Silicones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 4: World 7-Year Perspective for Silicones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 5: World Current & Future Analysis for Fluoroelastomers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 6: World 7-Year Perspective for Fluoroelastomers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 7: World Current & Future Analysis for Polyurethanes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 8: World 7-Year Perspective for Polyurethanes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 9: World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 10: World 7-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 11: World Current & Future Analysis for Consumer Electronics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 12: World 7-Year Perspective for Consumer Electronics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 13: World Current & Future Analysis for Medical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 14: World 7-Year Perspective for Medical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 15: World Current & Future Analysis for Industrial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 16: World 7-Year Perspective for Industrial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 17: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 18: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 III. MARKET ANALYSISUNITED STATES Market Facts & Figures Market Analytics Table 19: USA Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 20: USA 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 21: USA Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 22: USA 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 CANADA Table 23: Canada Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 24: Canada 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 25: Canada Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 26: Canada 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 JAPAN Table 27: Japan Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 28: Japan 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 29: Japan Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 30: Japan 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 CHINA Table 31: China Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 32: China 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 33: China Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 34: China 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 EUROPE Market Facts & Figures Market Analytics Table 35: Europe Current & Future Analysis for Wearable Materials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 36: Europe 7-Year Perspective for Wearable Materials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 Table 37: Europe Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 38: Europe 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 39: Europe Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 40: Europe 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 FRANCE Table 41: France Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 42: France 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 43: France Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 44: France 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 GERMANY Table 45: Germany Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 46: Germany 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 47: Germany Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 48: Germany 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 ITALY Table 49: Italy Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 50: Italy 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 51: Italy Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 52: Italy 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 UNITED KINGDOM Table 53: UK Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 54: UK 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 55: UK Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 56: UK 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 REST OF EUROPE Table 57: Rest of Europe Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 58: Rest of Europe 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 59: Rest of Europe Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 60: Rest of Europe 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 ASIA-PACIFIC Table 61: Asia-Pacific Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 62: Asia-Pacific 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 63: Asia-Pacific Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 64: Asia-Pacific 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 REST OF WORLD Table 65: Rest of World Current & Future Analysis for Wearable Materials by Type - Silicones, Fluoroelastomers, Polyurethanes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 66: Rest of World 7-Year Perspective for Wearable Materials by Type - Percentage Breakdown of Value Sales for Silicones, Fluoroelastomers, Polyurethanes and Other Types for the Years 2020 & 2027 Table 67: Rest of World Current & Future Analysis for Wearable Materials by Application - Consumer Electronics, Medical, Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 68: Rest of World 7-Year Perspective for Wearable Materials by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Medical, Industrial and Other Applications for the Years 2020 & 2027 IV. COMPETITIONTotal Companies Profiled: 45Read the full report: https://www.reportlinker.com/p06033294/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • What Stock Market Sell-Off? These Stocks Are Red Hot

    While a major index recently entered correction territory, one group of stocks has continued surging.

  • Glenfarne Group and Partners Group Announce EnfraGen’s Expanded Presence in Colombia Through Termovalle Acquisition

    EnfraGen, LLC ("EnfraGen"), a developer, owner, and operator of grid stability and value-added renewable power and assets in Latin America, jointly owned by Glenfarne Group and Partners Group, on behalf of its clients, announced today the close of its acquisition of Termovalle S.A.S. E.S.P., the largest natural gas-fired plant in Western Colombia. The sellers are Juneau Business Inc., Termovalle Investment Limited, Altra Private Equity Fund II LP, Altra Private Equity Fund II-A, Fondo de Capital Privado Altra FCP II and Altra Investments II GP Inc. With an installed capacity of 241 MW, the acquisition brings EnfraGen’s portfolio of operating and in-construction power assets to a combined capacity of approximately 1.7 GW. Following the acquisition, Termovalle will be renamed Prime Termovalle S.A.S. E.S.P.

  • Global Greeting Cards Market Trajectory & Analytics Report 2021 - ResearchAndMarkets.com

    The "Greeting Cards - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

  • Saudi wealth fund PIF to support corporate credit growth, S&P says

    Investments by Saudi Arabia's wealth fund Public Investment Fund (PIF) will support credit growth among companies in the kingdom, ratings agency S&P Global Ratings said on Monday. "The Public Investment Fund has recently announced investment initiatives that we expect will spur corporate credit growth, mostly in construction-related industries," S&P said. Domestic credit growth in Saudi Arabia, the biggest Arab economy, is expected to stay strong this and next year after a 14% year-on-year increase in 2020, S&P said.

  • OSS to Participate at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

    ESCONDIDO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (Nasdaq: OSS), a leader in specialized high-performance edge computing, has been invited to participate at the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021. The conference will feature presentations from public and private companies across a variety of industry sectors, followed by one-on-one and small group meetings, as well as expert panels and fireside chats. Past events have featured more than 550 participating companies and drawn more than 5,000 attendees, including institutional investors, analysts, family offices and high-net-worth investors. OSS president and CEO, David Raun, will participate in one-on-one meetings with investors and analysts during the conference. He will be joined by the company’s CFO, John Morrison, and chief sales and marketing officer, Jim Ison. To submit a registration request, click here. To schedule a one-on-one meeting with OSS, please contact your ROTH representative. For any questions about the company, contact Ron Both of CMA at (949) 432-7557 or submit your request here. About ROTH Capital PartnersROTH Capital Partners, LLC “ROTH” is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately held and employee owned. For more information on ROTH, please visit www.roth.com. About One Stop SystemsOne Stop Systems, Inc. (OSS) designs and manufactures innovative specialized high-performance computing modules and systems, including customized servers, compute accelerators, expansion systems, flash storage arrays and Ion Accelerator storage software. These products are used for deep learning, AI, defense, finance and entertainment applications, and empower scientists, engineers, creators and other professionals to push the boundaries of their industries. OSS utilizes the power of PCI Express, the latest GPU accelerators and NVMe storage to build award-winning systems, including many industry firsts, for OEMs and government customers. The company enables AI on the Fly® by bringing AI datacenter performance to ‘the edge’ and on mobile platforms, and by addressing the entire AI workflow, from high speed data acquisition to deep learning, training and inference. OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com. Forward-Looking StatementsOne Stop Systems cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by One Stop Systems or its partners that any of our plans or expectations will be achieved. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in our business, including, without limitation: risks associated with the fitness of One Stop Systems products and applications in certain industries; risks associated with the performance of our products that are combined into a third party's product, system, or application; and other risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Media Contact:Katie RiveraOne Stop Systems, Inc.Tel (760) 745-9883Email contact Investor Relations:Ronald Both or Grant StudeCMATel (949) 432-7557Email contact

  • Consolidated Water to Participate at the Virtual 33rd Annual ROTH Conference on March 15-17, 2021

    GEORGE TOWN, Cayman Islands, March 08, 2021 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading developer and operator of advanced water supply and treatment plants, has been invited to present at the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021. The conference will feature presentations from public and private companies across a variety of industry sectors, followed by one-on-one and small group meetings, as well as expert panels and fireside chats. Past events have featured more than 550 participating companies and drawn more than 5,000 attendees that include institutional investors, analysts, family offices and high-net-worth investors. Consolidated Water CEO, Rick McTaggart, will participate in one-on-one meetings with investors and analysts during the conference. He will be joined by the company’s CFO, David Sasnett. Management will discuss matters of interest to investors, including the company’s performance through the ongoing COVID-19 pandemic and growth opportunities in its recently acquired subsidiary, PERC Water Corporation located in Southern California. To submit a registration request, click here. To schedule a one-on-one meeting with Consolidated Water, please contact your ROTH representative. For any questions about the company, contact Ron Both of CMA at (949) 432-7557 or submit your request here. About ROTH Capital PartnersROTH Capital Partners, LLC “ROTH” is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately held and employee owned. For more information on ROTH, please visit www.roth.com. About Consolidated Water Co. Ltd.Consolidated Water Co. Ltd. develops and operates advanced water supply and treatment plants and water distribution systems. The company operates water production facilities in the Cayman Islands, The Bahamas and the British Virgin Islands and operates water treatment facilities in the United States. The company also manufactures and services a wide range of products and provides design, engineering, management, operating and other services applicable to commercial and municipal water production, supply and treatment, and industrial water and wastewater treatment. For more information, visit www.cwco.com. Company Contact:David W. SasnettExecutive Vice President and CFOTel (954) 509-8200dsasnett@cwco.com Investor Relations ContactRon Both, CMATel (949) 432-7566CWCO@cma.team

  • Cloud Computing Could Eliminate a Billion Metric Tons of CO2 Emission Over the Next Four Years, and Possibly More, According to a New IDC Forecast

    IDC estimates that cloud computing could prevent the emission of more than 1 billion metric tons of carbon dioxide (CO2) from 2021 through 2024.

  • Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference

    CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen, will present at the Oppenheimer 31st Annual Healthcare Conference being held March 16-18 2021. Qualigen Therapeutics, Inc. Presentation Details are as follows: Date: Wednesday, March 17, 2021 Time: 3:00 pm EDT. Management will be available throughout the day on March 17, 2021 for virtual one-on-one meetings. Conference: Oppenheimer 31st Annual Healthcare Conference (virtual) will provide investors a broad spectrum of public and private healthcare companies spanning all major sectors of the healthcare industry: bio & specialty pharmaceuticals; biotechnology; medical devices; life science tools and diagnostics; healthcare information technology and distribution; and healthcare providers and servicers. About Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack® System, which has been used successfully in diagnostics for 20 years. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational nucleolin-targeting DNA aptamer of ALAN, AS1411, is also a drug candidate for use in treating COVID-19 and other viral-based infectious diseases. RAS-F is a family of RAS oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Because Qualigen's therapeutic candidates are still in the development stage, Qualigen's only products that are currently commercially available are FastPack System diagnostic instruments and test kits, used in physician offices, clinics and small hospitals around the world. The FastPack System menu includes rapid point-of-care diagnostic tests for cancer, men's health, hormone function, vitamin D status and antibodies against SARS-CoV-2. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC. For more information on Qualigen Therapeutics, Inc., please visit https://www.qualigeninc.com/. Forward-Looking Statements This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. Actual events or results may differ from the Company’s expectations. For example, there can be no assurance that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline; that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development of the Company's drugs or therapeutic devices will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that patents will issue on the Company’s owned and in-licensed patent applications; that such patents, if any, and the Company’s current owned and in-licensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company’s prospective therapeutic products; that the Company will be able to maintain or expand market demand and/or market share for the Company’s diagnostic products generally, particularly in view of COVID-19-related deferral of patients’ physician-office visits and FastPack reimbursement pricing challenges; that adoption and placement of FastPack PRO System instruments (which are the only FastPack instruments on which the Company's SARS-CoV-2 IgG test kits can be run) will be widespread; that the Company will be able to manufacture the FastPack PRO System instruments and SARS-CoV-2 IgG test kits successfully; that any commercialization of the FastPack PRO System instruments and SARS-CoV-2 IgG test kits will be profitable; or that the FDA will ultimately approve an Emergency Use Authorization for the Company’s SARS-CoV-2 IgG test. The Company’s stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business (including events beyond the Company's control, such as epidemics and resulting changes) can be found in the Company's prior filings with the Securities and Exchange Commission, available at www.sec.gov. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Relations: David Kugelman, President and CEOAtlanta Capital Partners, LLC(404) 856-9157 Office(866) 692-6847 Toll Free - U.S. & Canadadk@atlcp.com Tony Schor, PresidentInvestor Awareness, Inc. (847) 971-0922tony@investorawareness.com

  • IDC Directions 2021 Defines Digital Resiliency to Support Organizations in a Changed World

    IDC announced details of IDC Directions 2021: Delivering Digital Resiliency in a Changed World, a two-day virtual event to be held March 9th and 16th.

  • Cooper Tire’s PRO Series™ LHT Now Standard Equipment on Vanguard Dry and Refrigerated Van Trailers

    Cooper Tire has announced that Vanguard National Trailer Corporation is including the Cooper® PRO Series™ LHT trailer tire as standard equipment on all dry and refrigerated van trailers built at its Monon, Ind.; Trenton, Ga.; Moreno Valley, Calif.; and Sarnia, Ontario, Canada locations.

  • Safe-T to Hold Global Technology Events With Its Leading Partners During March

    HERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- Safe-T® Group Ltd. (NASDAQ, TASE: SFET), a provider of secure access solutions and intelligent data collection, announces today that its wholly owned subsidiary, Safe-T Data A.R Ltd., will host several virtual technology events during March, in collaboration with its European partners, as follows: Topic: “The Explosion of Cyber Attacks in 2020 and How to Prevent Them in 2021” Safe-T Speaker: Eitan Bremler, Co-Founder & VP corporate Development March 10, 2021 at 11am (Israel time) – in collaboration with Softprom DACH, registration to the event is available here;March 11, 2021 at 12:00 (Israel time) – in collaboration with AERAsec Germany, registration to the event is available here. Additional virtual events will be held by Safe-T in collaboration with its European partners in Italy, Switzerland, Netherlands, and Sweden. Safe-T will also hold two events titled "To VPN or not to VPN", in collaboration with its partners in Mexico and the UK. The timing of these events, and registration details, will be provided separately on Safe-T’s website, www.safe-t.com About Safe-T® Safe-T Group Ltd. (Nasdaq, TASE: SFET) is a provider of access solutions and intelligent data collection. Our cloud and on-premises solutions mitigate attacks on enterprises’ business-critical services and sensitive data, while ensuring uninterrupted business continuity. Organization’s access use cases, whether into the organization or from the organization out to the internet, are secured according to the “validate first, access later” philosophy of Safe-T’s zero trust. This means that no one is trusted by default from inside or outside the network, and verification is required from everyone trying to gain access to resources on the network or in the cloud. The wide range of access solutions, empowered by our patented reverse-access technology and proprietary routing technology, reduce organizations’ attack surface, improve their ability to defend against modern cyberthreats and enable them smooth digital transformation and to safely migrate to the cloud. We also offer intelligent data collection cloud service, based on our world’s fastest and most advanced & secured business proxy network which enables clients to collect accurate, transparent & sensitive data from public online sources. Safe-T’s solutions on AWS Marketplace are available here For more information about Safe-T, visit www.safe-t.com Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Safe-T is using forward-looking statements in this press release when it discusses participation at future virtual events. Because such statements deal with future events and are based on Safe-T’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Safe-T could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Safe-T’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 31, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Safe-T undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Safe-T is not responsible for the contents of third-party websites. Investor Relations Contacts Chris Tyson Executive Vice President MZ Group - MZ North America 949-491-8235 SFET@mzgroup.us www.mzgroup.us Michal Efraty+972-(0)52-3044404 michal@efraty.com

  • Fieldpoint Private Surpasses Two Major Milestones

    Firm Tops $1 Billion in Bank Assets, $5 Billion in Investment AssetsGREENWICH, Conn., March 08, 2021 (GLOBE NEWSWIRE) -- Fieldpoint Private, the fast-growing wealth advisory and private banking boutique serving families and institutions, announced it has surpassed the $1 billion threshold in total bank assets, and $5 billion in total wealth management assets. The 12-year-old firm now ranks within the top 20 percent of U.S. banks by assets, and was recently named among America’s top 100 independent investment firms by Barron’s magazine. Since its 2008 founding in Greenwich, Connecticut, Fieldpoint Private has grown its presence to include New York City, Georgia and Florida, earning the business of families, entrepreneurs, businesses and charitable institutions in 46 states. It has attracted leadership, advisors and bankers from Bank of America, BNY Mellon, Brown Brothers Harriman, Citigroup, Goldman Sachs, J.P. Morgan, Morgan Stanley, Merrill Lynch, Neuberger Berman, Wells Fargo and others, as well as deeply rooted community banks. Chairman and CEO Tim Tully said that while it is important to take a moment to recognize these milestones, growth - by itself - was never the firm’s mandate. “Our goal has always been to create a new standard of service for clients, to maintain independence of thought and protect our commitment to do what’s right for the client, wherever that takes us.” He added, “It’s clearly taking us to a pretty good place, and I’m grateful to our colleagues for all they have done to get us here, and to our clients for their trust and enthusiasm along the way.” Russell Holland, President and CEO of Fieldpoint Private’s banking unit, said that when Fieldpoint was founded, clients could get commercial and personal banking, along with investment advice at any number of the giant global firms. “But clients felt the advice and experience was disconnected and too often met the interests of the firm more than themselves and their families,” he said. Christopher DeLaura, President and CEO of the firm’s wealth management unit added, “Delivering all of this, in a boutique experience, with fully integrated advice and world-class intellectual capital, was something no one had tried before. These milestones tell us it was an important idea at the right time, and we feel like we are just getting started.” About Fieldpoint PrivateHeadquartered in Greenwich, Connecticut, Fieldpoint Private (www.fieldpointprivate.com) is a boutique financial firm providing the highest degree of personalized, confidential wealth planning and private banking services. Catering to highly successful individuals, families, businesses and institutions, Fieldpoint Private offers a powerful combination of wealth management and strategy, family office, private banking and business banking services addressing every financial need for each of our clients including: wealth transfer advice, tax planning, aggregation and performance reporting, risk management, goals-based investing strategies, sophisticated investment selection, discreet and personalized banking, highly customized credit solutions, custom custody and trust solutions, highly attentive and responsive service, and concierge services. Fieldpoint Private was established in 2008 by 31 Founders with a specific vision and purpose. These extraordinary leaders of industry and community recognized the opportunity to create a financial firm totally attuned to people’s individual circumstances. Our firm is built on a philosophy of exclusive membership and client-centricity. Working with a limited number of relationships gives every person the experience of belonging to an extremely selective group. The result is a new breed of institution established on the basis of personalization, responsiveness, and exclusivity, and an ensured commitment to impeccable service and consistently flawless execution. Our service approach offers a unique client experience custom crafted to each client’s financial needs. Banking Services: Fieldpoint Private Bank & TrustRegistered Investment Advisors: Fieldpoint Private Securities, LLC, is a SEC Registered Investment Advisor and Broker Dealer. Member FINRA, MSRB, SIPC. CONTACT: Media Contact: Michael White Chief Marketing Officer Fieldpoint Private 203.413.9340 mwhite@fieldpointprivate.com

  • Saatchi Art Presents the Launch of The Other Art Fair Virtual Editions, An Innovative New Virtual Reality Art Fair Series

    In Partnership with BOMBAY SAPPHIRE®, the Global Launch of these VR Art Fairs Offers Guests Unique Programming, Live Experiences and Unparalleled Access to Top Emerging Artists SANTA MONICA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- The Other Art Fair, a leading artist fair for discovering emerging artists, will launch its new virtual reality art fair series with The Other Art Fair Global Virtual Editions on March 10-14. This debut Global Virtual Edition event will feature 75 of The Other Art Fair’s top emerging artists from around the globe within a three-dimensional virtual fair environment -- no headset required. The event will be supported by an immersive online program hosted on theotherartfair.com that will bring the unique experience of attending one of The Other Art Fair’s live events to life virtually for a global audience. “The Other Art Fair is known for creating a highly experiential program for fairgoers, while providing them access to exciting new emerging artists,” said Ryan Stanier, founder of The Other Art Fair. “Our new Virtual Edition fairs beautifully adapt that in-real-life experience to our innovative virtual platform, offering participants the chance to explore artist booths, participate in live fair tours, workshops and lectures, and gain direct access to the exhibiting artists, all from the comfort of their computer or phone.” The Global Virtual Edition kicks off the worldwide 2021 virtual fair tour for The Other Art Fair, which will include dedicated virtual events for all Fair exhibitions, including events in Los Angeles, London, Sydney, Brooklyn, Chicago, Dallas, and Toronto. Each Virtual Edition event will also feature workshops and VR programming unique to that city, creating a special experience that celebrates each market and its local art community. A signature element to every The Other Art Fair event is the direct connection attendees have to exhibiting artists. The Virtual Edition allows fairgoers to schedule a live chat with an exhibiting artist for a one-on-one discussion about the artist’s process, key artworks for sale and a chance to learn more about the artist’s background. Added Sean Moriarty, CEO of Leaf Group, “at Leaf Group, we are constantly striving to create the best experience possible for our audiences, and we are excited for the launch of The Other Art Fair’s first virtual reality fair. This innovative program further strengthens our mission of supporting artists worldwide through a virtual reality platform that connects them with a global art collector audience.” The Other Art Fair Global Virtual Edition runs from March 10-14, with Artist Room Preview Days on March 10, 11, 12. The event will showcase 75 of the top emerging artists, supported by a program of interactive virtual content. Some highlights from the Global Virtual Edition programming include: Chat With An Artist: Opportunities to meet and talk to the talented exhibiting artists about their work, inspiration and process, or to see an artwork in more detail and ask questions about a specific piece.Virtual Editions Live Talks, Workshops and Tours: Explore the artist’s studios through engaging talks and tours that uncover the creative process behind many of the works on display at the Virtual Edition. All free to register, talks and tours will include: º Bombay & Tonic Customization with Valentino Longo: The Other Art Fair has partnered with BOMBAY SAPPHIRE® to create a virtual workshop for guests to learn about the BOMBAY & Tonic, why the two pair together so well, and how to make three upgraded versions at home. Guests must be of legal drinking age to view and share this workshop. º Invest in Art with Rebecca Wilson: Join Saatchi Art’s Chief Curator Rebecca Wilson as she shares what to look for when investing in emerging artists. º Artistic Process: For many artists, the process is just as important as the finished product. Saatchi Art Curator Megan Wright introduces the makers of some of the fair’s most popular artworks to gain insights into their creation. º Live Fair Tours of Artist Rooms 1, 2, and 3: LA and Dallas Fair Director Nicole Garton introduces her top artists from Artist Room 1; London Fair Manager Anouka Pedley introduces her top artists from Artist Room 2; East Coast Fair Assistant Sasha Ali introduces her top artists from Artist Room 3. Build Your Own Happy Character - An Interactive Experience by Eva Cremers: Through an interactive experience, visitors can tap into their own cheeky, creative side with an interactive, drag-and-drop tool that allows you to create your own Happy Character.Gommie Live Poetry Reading: Artist and poet Gommie will perform live and showcase some of his artwork.Girls in Film Short Film Screenings: Girls in Film represents, champions and connects the new generation of female-identified creatives in the film industry. The organization has curated a selection of five short films for The Other Art Fair to showcase rising filmmakers from London, South Africa, Prague and Amsterdam. ARTIST ROOMS The featured artists will be showcased across three rooms to allow the visitor to more easily digest all artist stands. Each Artist Room will also contain exclusive experiential content and have its own dedicated Preview day, providing a first look at that Artist Room’s exhibitors while the other rooms are closed. Visitors are encouraged to pre-register, for free access to these Previews. All rooms will be carefully curated by the fair team to ensure an exciting and varied breadth of medium. Visitors can also take a pre-recorded ‘Room Highlights' tour by the Fair Director before they enter. ROOM 1 | Preview on Wednesday, March 10Discover bright colors, fun sculptural works, inspirational portraits, plus much more ROOM 2 | Preview on Thursday, March 11Get lost in large-scale abstracts, thoughtful photography, poetry, street art, plus more ROOM 3 | Preview opens on Friday, March 12 Be swept away by some beautiful paintings, enchanting illustrations, photography, and more To learn more about The Other Art Fair Global Virtual Edition, visit https://www.theotherartfair.com/. About The Other Art FairThe Other Art Fair, a leading artist fair for discovering emerging artists, provides a platform for artists to present and sell their work directly to art buyers both through in-person events and online. Each fair presents more than 90 artists chosen by a selection committee of art experts, enabling both collectors and first-time buyers to buy directly from emerging artists. Since 2011, The Other Art Fair has worked with over 3,000 artists from more than 20 countries, with fairs based in the UK, US and Australia. Unlike “other” fairs, The Other Art Fair creates an accessible and open fair designed for visitors to enjoy an interactive and immersive experience. www.theotherartfair.com About Saatchi ArtLeading online art gallery Saatchi Art features one of the world’s largest selections of original art and helps people all over the world find art and artists they love. The online art gallery offers original paintings, drawings, sculptures and photographs by over 100,000 emerging artists from over 100 countries. Saatchi Art is redefining the experience of buying and selling art by providing art lovers with free art advisory services and an expertly curated selection of art, while giving artists a convenient and welcoming environment in which to exhibit and sell their work. To discover the world of Saatchi Art, please visit www.saatchiart.com. Saatchi Online, Inc., which operates Saatchi Art, is a wholly owned subsidiary of Leaf Group Ltd. (NYSE: LEAF). About Leaf GroupLeaf Group Ltd. (NYSE: LEAF) is a diversified consumer internet company that builds enduring, creator-driven brands that reach passionate audiences in large and growing lifestyle categories, including fitness & wellness (Well+Good, Livestrong.com and MyPlate App), and home, art & design (Saatchi Art, Society6 and Hunker). For more information about Leaf Group, visit www.leafgroup.com. Media Contact:Sharna DadukVP, Communicationssharna.daduk@leafgroup.com Mia MendezDirector, Public Relationsmia.mendez@leafgroup.com

  • Veru Exploring Strategic Alternatives for its Legacy Female Health Business

    MIAMI, March 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer, today announced that it has engaged Morgan Stanley & Co. LLC as a financial advisor to assist the Company and its management in pursuing strategic alternatives regarding its legacy FC2 Female Condom® / FC2 Internal Condom business (FHC Business). “With the last two consecutive quarters for our FHC Business having set all-time historical records in terms of net revenues and gross profit, and with the last three-year compound annual growth rates for the FHC Business’ net revenues and gross profit being 60% and 83%, respectively, we think this is an ideal time to consider strategic alternatives, including the possibility of monetizing this business, as we recently did with our PREBOOST business,” said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer. “Furthermore, with the potential for five registration clinical trials in calendar year 2021 -- four for oncology indications and one for COVID-19 — it is clear that Veru has transformed itself into a premium, late-stage, clinical biopharmaceutical company, so the strategic fit with the FHC Business is not as strong as it once was.” Dr. Steiner added: “The FHC Business has been a great business for Veru. Fiscal year 2020 was a record year in terms of net revenues of $41 million and gross profit of $29 million, and Q1 fiscal year 2021 is already off on another record-setting pace. The cash flow generated by the FHC Business has allowed Veru to significantly advance its biopharmaceutical clinical programs. We are open to exploring the right kind of strategic transaction for the FHC Business with a view towards the best, long-term interests of Veru shareholders, which may include continuing to operate the FHC Business if we ultimately decide that is in our shareholders’ best interests.” About the FHC BusinessThe FHC Business is Veru’s legacy business. Its commercial product is the FC2 Female Condom®/ FC2 Internal Condom (“FC2”), the only FDA approved female condom that provides dual protection against unintended pregnancy and the transmission of sexually transmitted infections. FC2 is sold commercially and in the public health sector both in the U.S. and globally. In the U.S., FC2 is available by prescription through multiple third-party telemedicine and internet pharmacy providers and retail pharmacies. In the global public health sector, the Company markets FC2 to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world. Over 650 million FC2 units have been sold globally in 159 countries. The FHC Business record growth has demonstrated a resiliency to the impact of the COVID-19 pandemic through a proven telemedicine prescription sales model. To learn more about the FC2 product, please visit www.verupharma.com "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: There can be no assurance that any FHC Business strategic transaction will occur and there is no definitive timetable for such. The Company does not intend to make future announcements concerning this matter, unless or until it enters into a definitive agreement, or its board of directors determines to conclude the process, or it otherwise deems that further disclosure is appropriate or required. The statements in this release that are not historical facts are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include statements regarding strategic alternatives with respect to, and the Company's ability to potentially monetize the Company's legacy FHC Business, and the anticipated timeframe for clinical studies and FDA submissions of the Company’s biopharmaceutical drug candidates. Any forward-looking statements in this release are based upon the Company's current plans and strategies and reflect the Company's current assessment of the risks and uncertainties related to its business and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release because of new information or future events, developments or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: the risk that the Company may not enter into a definitive agreement or otherwise proceed with any transaction regarding its FHC Business; costs, fees and expenses related to the process of exploring strategic alternatives with respect to the FHC Business and the risk that the process may divert management’s attention from managing our business operations; risks related to the development of the Company's product portfolio, including clinical trials, regulatory approvals and time and cost to bring to market; potential delays in the timing of and results from clinical trials and studies, including potential delays in the recruitment of patients and their ability to effectively participate in such trials and studies due to COVID-19, and the risk that such results will not support marketing approval and commercialization; potential delays in the timing of any submission to the FDA and regulatory approval of products under development and the risk that disruptions at the FDA caused by the COVID-19 pandemic may delay the review of submissions or approvals for new drugs; the risk of a delay or failure in reaching agreement with the FDA on the design of a clinical trial or in obtaining authorization to commence a clinical trial; preclinical or clinical results or early data from clinical trials may not be replicated or continue to occur in additional trials or may not otherwise support further development in the specified product candidate or at all; our pursuit of a COVID-19 treatment candidate is at an early stage and we may be unable to develop a drug that successfully treats the virus in a timely manner, if at all; risks related to our commitment of financial resources and personnel to the development of a COVID-19 treatment which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties about the longevity and extent of COVID-19 as a global health concern and the possibility that as vaccines become widely distributed the need for new COVID-19 treatment candidates may be reduced or eliminated; government entities may take actions that directly or indirectly have the effect of limiting opportunities for VERU-111 as a COVID-19 treatment, including favoring other treatment alternatives or imposing price controls on COVID-19 treatments; the risk that the Company's products may not be commercially successful; risks related to the impact of the COVID-19 pandemic on our business, the nature and extent of which is highly uncertain and unpredictable; risks relating to the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations, including our ability to secure timely grant or other funding to develop VERU-111 as a potential COVID-19 treatment; product demand and market acceptance; competition in the Company's markets and therapeutic areas and the risk of new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions; the risk that the Company will be affected by regulatory developments, including a reclassification of products; price erosion, both from competing products and increased government pricing pressures; manufacturing and quality control problems; compliance and regulatory matters, including costs and delays resulting from extensive governmental regulation, and effects of healthcare insurance and regulation, including reductions in reimbursement and coverage or reclassification of products; some of the Company's products are in development and the Company may fail to successfully commercialize such products; risks related to intellectual property, including the uncertainty of obtaining patents, the effectiveness of the patents or other intellectual property protections and ability to enforce them against third parties, the uncertainty regarding patent coverages, the possibility of infringing a third party’s patents or other intellectual property rights, and licensing risks; government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government tenders and contracts may be subject to cancellation, delay, restructuring or substantial delayed payments; the risk that delays in orders or shipments under government tenders or the Company’s U.S. prescription business could cause significant quarter-to-quarter variations in the Company’s operating results and adversely affect its net revenues and gross profit; a governmental tender award indicates acceptance of the bidder's price rather than an order or guarantee of the purchase of any minimum number of units, and as a result government ministries or other public sector customers may order and purchase fewer units than the full maximum tender amount or award; penalties and/or debarment for failure to satisfy tender awards; the Company's reliance on its international partners and on the level of spending by country governments, global donors and other public health organizations in the global public sector; risks related to concentration of accounts receivable with our largest customers and the collection of those receivables; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints and interruptions, including potential disruption of production at the Company’s and third party manufacturing facilities and/or of the Company’s ability to timely supply product due to labor unrest or strikes, labor shortages, raw material shortages, physical damage to the Company’s and third party facilities, COVID-19 (including the impact of COVID-19 on suppliers of key raw materials), product testing, transportation delays or regulatory actions; risks related to the costs and other effects of litigation, including product liability claims; the Company's ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company's ability to successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the fiscal year ended September 30, 2020 and subsequent quarterly reports on Form 10-Q. These documents are available on the "SEC Filings" section of our website at www.verupharma.com/investors. Investor Contact:Sam Fisch veruinvestor@verupharma.comDirector of Investor Relations Corporate Development Contact:Kevin Gilbert kgilbert@verupharma.comEVP Corporate Development

  • NaturalShrimp, Inc Announces Filing of Shelf Registration Statement for the Sale of Up to $100 Million of its Securities

    Dallas, TX, March 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire--NaturalShrimp, Inc. (OTCQB:SHMP), an aquaculture company which has developed and patented the first commercially operational Recirculating Aquaculture System (RAS) for shrimp, announced today that it has filed a primary shelf registration statement on Form S-3 to sell up to $100 million of its securities. Any potential offerings are subject to the Form S-3 being declared effective by the Securities and Exchange Commission (the “SEC”), market and other conditions, and there can be no assurance as to whether or when any offerings may be completed, or as to the actual size or terms of the offerings. If one or more offerings are completed, all of the securities in the offerings will be sold by NaturalShrimp, Inc. If the SEC declares the Form S-3 effective then securities may be offered only by means of a written prospectus, including a prospectus supplement, forming a part of the effective registration statement. An electronic prospectus supplement and the accompanying prospectus relating to any offerings will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor there any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Forward Looking Statements This press release contains "forward-looking statements." The statements contained in this press release that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current expectations or forecasts of future events. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond the Company's control, and could cause the Company's results to differ materially from those described. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements include statements regarding moving forward with executing the Company's global growth strategy. The statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The Company is providing this information as of the date of this press release and does not undertake any obligation to update any forward looking statements contained in this press release as a result of new information, future events or otherwise, except as required by law. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Important factors that could cause such differences include, but are not limited to the Risk Factors and other information set forth in the Company's Annual Report on Form 10-K filed on June 26, 2020, and in our other filings with the U.S. Securities and Exchange Commission. Contact:Richard Brown(508).462.9638 SOURCE: Natural Shrimp